Enzon Pharmaceuticals, Inc. (ENZN)
Stock Price:
$0.200 USD
0.000 (0.00%)
Updated Aug 6, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
8.84M |
| Revenue (ttm) |
61,000 |
| Net Income (ttm) |
-1.07M |
| Shares Out |
44.21M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
$0.12 |
| Dividend Yield |
60.00% |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$0.200 |
| Previous Close |
$0.200 |
| Change ($) |
0.000 |
| Change (%) |
0.00% |
| Day's Open |
0.190 |
| Day's Range |
0.190 - 0.220 |
| Day's Volume |
77,683 |
| 52-Week Range |
0.135 - 0.305 |
More Stats
| Market Cap |
8.84M |
| Enterprise Value |
2.93M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.21M |
| Float |
27.36M |
| EPS (basic) |
-0.03 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
0.18 |
| Dividend |
$0.12 |
| Dividend Yield |
60.00% |
| Earnings Yield |
n/a |
| FCF Yield |
88.75% |
| Payout Ratio |
n/a |
| Shares Short |
157,472 |
| Short Ratio |
1.03 |
| Short % of Float |
0.41% |
| Beta |
0.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
1.13 |
| PS Ratio |
144.97 |
| PB Ratio |
1.35 |
| Revenue |
61,000 |
| Operating Income |
-1.06M |
| Net Income |
-1.07M |
| Free Cash Flow |
7.85M |
| Net Cash |
5.91M |
| Net Cash / Share |
0.13 |
| Gross Margin |
339.34% |
| Operating Margin |
-1,736.07% |
| Profit Margin |
-1,745.90% |
| FCF Margin |
12,865.57% |
| ROA |
-7.19% |
| ROE |
-12.15% |
| ROIC |
153.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
16.0
Current: $0.200
High
16.0
Target: 16.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.21 | 6.92 | 8.38 | 8.38 | 17.46 | 31.17 | 34.49 | 42.60 | 48.07 | 97.87 |
| Revenue Growth | -97.01% | -17.44% | 0.02% | -52.01% | -44% | -9.63% | -19.03% | -11.38% | -50.88% | - |
| Gross Profit | 0.21 | 6.92 | 8.38 | 8.38 | 17.46 | 31.17 | 34.49 | 42.60 | 48.07 | 97.87 |
| Operating Income | -0.97 | 5.86 | 7.01 | 6.64 | 10.80 | 28.79 | 18.16 | -3.97 | -16.46 | -0.58 |
| Net Income | -0.98 | 5.85 | 5.45 | -1.13 | 21.64 | 28.80 | 18.15 | -2.78 | -20.76 | 177 |
| Shares Outstanding | 44.22 | 44.22 | 44.22 | 44.22 | 44.20 | 44.13 | 43.78 | 46.74 | 51.91 | 58.47 |
| Earnings Per Share | -0.02 | 0.13 | 0.12 | -0.03 | 0.49 | 0.65 | 0.38 | -0.06 | -0.40 | 3.03 |
| EPS Growth | - | 8.33% | - | - | -24.62% | 71.05% | - | - | - | - |
| Dividend Per Share | 0.12 | - | 0.15 | 0.15 | 0.85 | - | 3.65 | 2.00 | - | - |
| Dividend Growth | - | - | 0% | -82.35% | - | - | 82.5% | - | - | - |
| Operating Cash Flow | 6.91 | -0.98 | 6.47 | 2.60 | 14.68 | 32.34 | 14.01 | 8.45 | -12.73 | 22.62 |
| Capital Expenditures | - | - | - | - | - | 0.15 | 2.23 | -0.01 | -0.63 | -1.97 |
| Free Cash Flow | 6.91 | -0.98 | 6.47 | 2.60 | 14.68 | 32.49 | 16.24 | 8.44 | -13.35 | 20.65 |
| Cash & Equivalents | 5.45 | 6.50 | 7.48 | 7.64 | 11.67 | 34.56 | 6.52 | 197 | 323 | 460 |
| Total Debt | - | - | - | - | - | - | - | 116 | 129 | 134 |
| Net Cash / Debt | 5.45 | 6.50 | 7.48 | 7.64 | 11.67 | 34.56 | 6.52 | 80.89 | 194 | 326 |
| Assets | 6.48 | 15.51 | 9.51 | 11.27 | 22.89 | 35.04 | 7.12 | 200 | 343 | 489 |
| Liabilities | 0.42 | 0.52 | 0.37 | 0.94 | 4.80 | 5.44 | 1.87 | 122 | 146 | 157 |
| Book Value | 6.06 | 14.99 | 9.14 | 10.33 | 18.09 | 29.60 | 5.26 | 77.47 | 197 | 332 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Enzon Pharmaceuticals, Inc. |
| Country |
United States |
| CEO |
Andrew D. Rackear |
Stock Information
| Ticker Symbol |
ENZN |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ENZN |
| IPO Date |
February 15, 1984 |
Description
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.